2017-18 Annual Report

Download the 2017-18 CBTTC Annual Report


2017-18 Children’s Brain Tumor Tissue Consortium Annual Report

 

Message from the Executive ChairsCBTTC Executive Chairs

Dear CBTTC Colleagues and Supporters,

It is with tremendous pride that we present the 2017-2018 CBTTC Annual Report. We are proud to say that the CBTTC has had another excellent year and we sincerely appreciate your contributions to our mission. CBTTC’s growth and expansion has continued with the addition of two new satellite sites. We are pleased to welcome Dayton Children’s Hospital in Dayton, Ohio as well as the Hudson Institute for Medical Research located in Melbourne, Australia. This outreach into Australia represents our effort to grow the CBTTC as an international consortium. The leadership team had the privilege of visiting Melbourne to help launch the Pediatric Precision Medicine Initiative and we are excited about future opportunities to collaborate and innovate with these colleagues.

We continue to experience growth in the number of patient samples and corresponding clinical and genomic data in our biobank. The CBTTC is the largest clinically annotated pediatric brain tumor database in the world and is supported by a robust bioinformatic infrastructure. Our mission is to support scientific projects using the CBTTC specimens or data, including 25 new projects that were reviewed and approved this year. Our visibility and branding of the CBTTC in the scientific and fundraising communities experienced exponential growth throughout the year. These efforts culminated with our support of the International Society of Pediatric Neuro-Oncology (ISPNO) meeting held in Denver in June of 2018. The meeting was a huge success for the CBTTC, including scientific presentations and engagement with researchers and supporters across the globe.

The CBTTC Advisory Council has also continued to grow and develop under the leadership of Allen Gustafson of the Swifty Foundation. In addition to their support and advice, this year they developed a mechanism to provide grant funding to each newly approved scientific project to help incentivize more innovative research projects. We remain indebted to the Advisory Council for their enduring support.

The end of this year also brings a number of leadership changes. As the outgoing and incoming CBTTC Executive Chairs, we are pleased to also announce that Jennifer Mason has been promoted to Director of Operations for the CBTTC and Elizabeth Appert has been promoted to Manager of CBTTC Operations. Drs. Adam Resnick and Javad Nazarian will continue their fantastic work as CBTTC Scientific Co-Chairs through June of 2019. Please join us in congratulating everyone on their new roles. We have no doubt that this team will work with you to ensure the continued success of the consortium.

With very best wishes,

Rishi and Angela


Rishi R. Lulla MD MS
Former Chair of the Executive Committee, Children’s Brain Tumor Tissue Consortium
Division Director, Pediatric Hematology/Oncology, Hasbro Children’s Hospital
Associate Professor of Pediatrics, The Warren Alpert Medical School of Brown University
Email: rishi_lulla@brown.edu


Angela J Waanders, MD, MPH
Current Chair of the Executive Committee, Children’s Brain Tumor Tissue Consortium
Director of Clinical Research, Center for Data Driven Discovery in Biomedicine (D3b)
Assistant Professor, Perelman School of Medicine University of Pennsylvania
Children’s Hospital of Philadelphia
Email: waandersa@email.chop.edu

 


Message from the Scientific Co-chairs

Javad Nazarian, PhD, MSc
Scientific Co-chair, Children’s Brain Tumor Tissue Consortium
Associate Professor, Integrative Systems Biology
George Washington University
School of Medicine and Health Sciences
Children’s National Medical Center
Principal Investigator, Children’s Research Institute (CRI)
Center for Genetic Medicine Research (CGMR)
Center for Cancer and Immunology Research (CCIR)

 

Adam Resnick, PhD
Scientific Co-chair, Children’s Brain Tumor Tissue Consortium
Scientific Co-chair, Pacific Pediatric Neuro-Oncology Consortium
Director, Center for Data Driven Discovery in Biomedicine (D3b)
Director for Neurosurgical Translational Research, Division of Neurosurgery
Children’s Hospital of Philadelphia

 

 

Dear CBTTC Colleagues,

This past year has been another landmark year throughout the Children’s Brain Tumor Tissue Consortium; achieving new records and milestones on behalf of our mission and CBTTC’s expanded biospecimen cohorts, preclinical model development, and data generation efforts. The CBTTC continues to be at the forefront of scientific discovery, supporting numerous investigator-initiated projects and multiple collaborative engagements and partnerships, as well as leading the development of new discovery platforms for generating, distributing, and analyzing large-scale multidimensional pediatric brain tumor molecular datasets alongside deep, longitudinal clinical data in support of translational impact. This past year, molecular characterization of biospecimens will be available after the launch of the Pediatric Brain Tumor Atlas (PBTA)* project, the largest pediatric brain tumor dataset to date. The CBTTC’s PBTA will comprise a key component of the newly created NIH-supported Gabriella Miller Kids First Data Resource Center (DRC). The PBTA will be released alongside the launch of the Kids First DRC Portal in September of 2018. This first-in-kind platform and initiative not only expands CBTTC’s role as a leader in biobanking, data sharing and scientific discovery, but further provides for the seamless integration of CBTTC data with more 25,000 human genomes across multiple diseases. The availability of such an immense data resource center will empower CBTTC members to accelerate discovery and development of effective treatments through cross-disease analyses and broader collaborations.

The accomplishments of the past year provided the CBTTC with a unique opportunity to be a leader in informing clinical and translational research. Indeed, over the past year, CBTTC’s partnership with the Pacific Pediatric Neuro-Oncology Consortium (PNOC) has expanded with its direct contribution to and support of ongoing clinical trials. Specifically, PNOC clinical trial data and CBTTC data are integrated in near-real time, and correlative studies and preclinical model development using specimens obtained during the clinical trials are integrated with CBTTC’s biorepository-based efforts. The preclinical models are further characterized by CBTTC, and data and models are made readily available to investigators. Such integrated partnerships have served to further support the launching of disease-specific initiatives including Project Open DIPG, which aims to support collaborative laboratory-based research and accelerate the collection, harmonization and dissemination of DIPG specimens, models and clinical data across one platform. This fall, OPEN DIPG will look to expand its collaborative impact as CBTTC member institutions will gather with other national and international colleagues in Washington, DC for a two-day meeting to discuss achievements in the field of DIPG clinical and translational research, and how collaborative initiatives, such as Project Open DIPG, can accelerate this research.

Over the next year, CBTTC will continue to expand resources and strengthen its commitments to biospecimen-driven discoveries with the single goal of accelerating treatment for childhood brain cancers. This will include support for multi-institutional team-based scientific initiatives and projects and the growth of the PBTA as well as enhanced integration with PNOC’s clinical trials. This past year has been transformational, but the coming year is poised for even greater impact and the CBTTC and it’s scientific committee look forward to even greater innovation through collaboration on behalf of children with brain tumors.

Warmest regards,

 

Adam Resnick, PhD
Children’s Hospital of Philadelphia

 

Javad Nazarian, PhD, MSc
Children’s National Health System

*For an update of the launch of the PBTA, read the press announcement


Year in Review

The 2017-2018 fiscal year demonstrated continued growth for the Children’s Brain Tumor Tissue Consortium under the strong leadership of Drs. Lulla, Waanders, Nazarian, and Resnick. We reached a landmark with over 2,500 subjects enrolled, with corresponding biospecimen, clinical and genomic data collections. Additionally, the consortium expanded the collaboration both nationally and internationally with the addition of two new satellite sites, Dayton Children’s Hospital in Ohio and the Hudson Institute for Medical Research in Australia. This further supports the breakdown of the traditional research landscape of siloed institutions by bringing additional experts into the collaborative space.

2017-18 Annual ReportKids First Data Resource CenterThe CBTTC remained focused on one of its on-going initiatives, to generate whole-genome sequencing and RNA sequencing on every biospecimen in the biorepository to create the world’s most comprehensive dataset of pediatric brain tumors, the Pediatric Brain Tumor Atlas (PBTA). This is a first-of-its-kind, comprehensive molecular and phenotypic database that spans every type of pediatric brain tumor diagnosis. Researchers across the world will have non-embargoed access to transform the discovery process and accelerate the translation of large-scale molecular and clinical datasets to novel therapeutic approaches.

With the the PBTA initiative, the CBTTC has partnered with the Kids First Data Resource Center (DRC) and the newly-developed Kids First Data Resource Portal. Organized in 2017, the Kids First Data Resource Center is a  National Institute of Health initiative to develop data-driven platforms, empower collaborative discovery and engagement, and enable rapid translation to personalized treatments. The Portal will provide access to newly-released, large-scale, pediatric genomic and clinical disease data, including the PBTA.

The CBTTC continued their model of providing open access to biospecimens within the biorepository and to datasets, which was exhibited through the increase of project requests and approvals throughout the year. Seven new biospecimen requests and 18 new data requests were approved, bringing the totals to 27 and 18, respectively.

The open access model provides researchers across the world biospecimens and data that may otherwise take years or decades to procure. One researcher was able to analyze CBTTC data for a particular brain tumor type in PedcBioportal, find a target, research therapies within the lab, and then take those discoveries and translate them into a clinical trial concept, all within a year. This remarkable forward momentum was only made possible by the collaborative open access nature of the CBTTC.

Pacific Pediatric Neuro-Oncology ConsortiumAdditionally, the CBTTC has continued its key collaboration with the Pacific Pediatric Neuro-Oncology Consortium (PNOC). PNOC has 18 member institutions and conducts clinical trials on children with brain tumors using a precision medicine approach. The results of those studies are continually shared with CBTTC to help support the discovery of new targeted therapies. Together the CBTTC and PNOC are focused on a shared mission – to help accelerate research discovery to help children diagnosed with brain tumors.

2017-18 Annual Report

 


4th Annual Investigator Meeting

May 7-8, 2018 at Children’s Hospital of Philadelphia

The 4th Annual CBTTC Investigator Meeting was hosted by the Children’s Hospital of Philadelphia and coincided with Childhood Brain Tumor Awareness month (May). We would like to extend a special thank you to the Perricelli Family for generously providing funds to support the meeting. On May 7th, the meeting began with a special dinner bringing together both researchers from our member institutions, foundation partners, and the operations team from Children’s Hospital of Philadelphia. Tammie Souza, Chief Meteorologist for NBC 10 in Philadelphia, spoke of her son’s battle with a brain tumor, which began at Lurie Children’s Hospital in Chicago, a CBTTC member institution, prior to their move to Philadelphia. Dr. Rishi Lulla provided operational updates and Dr. Jay Storm honored Dr. Peter Phillips and his role in creating the consortium.

 

 

 

 

 

 

 

On May 8th, the meeting program included scientific sessions and overall operational status updates. Dr. Ron Firestein of the Hudson Institute for Medical Research in Australia and one of CBTTC’s newest members, delivered the keynote address. This was followed by the investigators presenting updates on their current CBTTC supported projects, utilizing CBTTC biospecimens and/or data. The meeting closed with updates from our international member sites.

 


CBTTC Member & Satellite Institutions


Growth of Research

This type of open-access data generation effort will accelerate development of brain tumor treatments by eliminating barriers that have historically existed, including a lack of access to biospecimens and patient related data.

– Angela Waanders, MD, MPH, CBTTC Executive Chair

CBTTC At A Glance

Number of Scientific (Specimen & Data) Project Cohorts Submitted and Approved by Fiscal Year


Scientific Project Updates

*The projects listed below were approved during the FY17-18 year

Specimen Projects

CBTTC_0020 – Dr. Mark Souweidane and Dr. Uday Maachani: Choroid Plexus Tumor (CPT) therapies based on patient-derived cell culture resources

CBTTC_0022 – Dr. Adam Resnick and Dr. Marilyn Li: BGI Validation Cohort

CBTTC_0023 – Dr. Adam Resnick and Dr. Brian Rood: Kids First – CBTTC Proteogenomic Pilot Project

CBTTC_0024 – Dr. Jessica Tsai and Dr. Christopher Walsh: Understanding developmental cell lineage in childhood medulloblastoma using single cell DNA sequencing technology

CBTTC_0027 – Dr. Amanda Saratsis and Dr. Rishi Lulla: Cracking the Histone Code: Characterizing Pediatric Brain Tumor Epigenetics using Cerebrospinal Fluid

CBTTC_0028 – Dr. Kristopher Bosse and Dr. Jessica Foster: GPC2 as an immunotherapeutic target in medulloblastoma and other pediatric brain tumors

CBTTC_0029 – Dr. Pablo Gonzalez Camara: Molecular Analysis of the Cellular Ecosystem of Childhood Ependymoma

Data Projects

CBTTC_D0001 – Dr. Hideho Okada: DIPG and other primary pediatric brain tumors

CBTTC_D0002 – Dr. Samuel Rivero-Hinojosa: Proteogenomic Identification of Structural Variations

CBTTC_D0003 – Dr. Jamie Anastas: Analysis of chromatin pathways asregulators of high grade glioma gene expression patterns

CBTTC_D0004 – Dr. Derek Wainwright: Derek Wainright on IDO1 expression with all the CBTTC RNA-Seq data

CBTTC_D0005 – Dr. Gonzalo Lopez Garcia: Telomere maintenance across multiple brain tumors

CBTTC_D0006 – Dr. Sri Priya Ponnapalli: Multi-Tensor Decompositions for Personalized Pediatric Glioma Diagnostics and Prognostics

CBTTC_D0007 – Dr. Peter Madsen: In silico neo-antigen detection in high grade pediatric brain tumors utilizing RNA-seq and WGS

CBTTC_D0009 – Birra Taha: Spatial evolution and somatic mutations spectrum of Gliomatosis Cerebri

CBTTC_D0010 – Dr. Charles Vaske: Integrative analysis of childhood cancers

CBTTC_D0011 – Dr. Sarah Leary: Malignant Cortical Tumors

CBTTC_D0012 – Dr. Sharon Diskin: Defining the mutational landscape of pediatric brain tumors

CBTTC_D0014 – Rohan Bareja: Fusion Analysis in CBTTC RNAseq data

CBTTC_D0015 – Dr. Thomas De Raedt: Cooperating mutations in brain tumors of patients with NF1

CBTTC_D0016 – Shimin Shuai: Identification of non-coding drivers from brain tumour genomes

CBTTC_D0017 – Dr. Sameer Agnihotri: Integrated Genomic Analysis to elucidate the role of PIKC3A and 10q LOH as unique drivers and cooperating events in pediatric high grade gliomas

CBTTC_D0020 – Julie Baran: Genetic Polymorphisms and Neurocognitive Outcomes in Pediatric Brain Tumor Survivors

CBTTC_D0021 – Dr. David Haussler: Treehouse Childhood Cancer Initiative: Identification of therapeutic leads for individual pediatric cancer patients via pan-cancer analysis

CBTTC_D0023 – Dr. Bonnie Cole: Comparison of Clinical Targeted Next Generation Sequencing (NGS) in FFPE with whole genome sequencing (WGS) of snap frozen pediatric brain tumors


Fiscal Year 2018 Financial Summary

The CBTTC is primarily supported through the generous philanthropic efforts of all its donors as well as additional infrastructure support provided by the Children’s Hospital of Philadelphia, including the Division of Neurosurgery and the Center for Data Driven Discovery in Biomedicine (D3b). CBTTC leadership and members continued to ensure fiscal responsibility of these funds. The FY18 budget totaled $939,635.23, made up of the following core areas:

  • Personnel
  • Travel
  • Supplies
  • Subcontracts (Site Support)
  • Cores (Biorepository Core)

A majority of the budget is directed toward site support. As part of the FY18 fiscal year objectives, the Executive Board instituted site metrics, whereby each site is evaluated for their contribution to theConsortium, including biospecimen/data submitted as well as site engagement by team members. At the end of FY18, sites were ranked based upon the agreed metric system and the Executive Board subsequently adjusted site support where identified. This evaluation supports sustainability of the consortium in addition to being mindful of donor funds.

 

 

Note: Other resources provided by Children’s Hospital of Philadelphia, not reflected in these numbers, include use of the Hospital’s state-of-the-are biorepository, bioinformatics platforms developed through other grants and mechanisms, additional staff support from the more than 60 members of D3b, and gift processing and donor relations support from the CHOP Foundation.

Message from the CBTTC Advisory Council

The Advisory Council of the CBTTC celebrated its first anniversary at the Investigator Meeting in May of 2018. Modeling the collaborative approach of the Consortium, the Advisory Council is made up of fourteen foundations invested in advancing the work of the CBTTC. Like research, philanthropy makes a greater impact through cooperation. The Council’s role is to advise, advocate and provide financial resources for the benefit of the CBTTC. This is a collaborative working body where all members play an active role.

The inaugural year of the Advisory Council began with the fourteen philanthropies getting to know one another, coming to an understanding of their collective interests and strengths. A communication plan was created that encouraged the CBTTC to develop more independent branding and united the voices of the Advisory Council members on social media and through a shared blog. The Council then created a scientific grant fund that provides supplemental financial support to new scientific projects that use CBTTC bio-specimens and/or data. In addition to their individual financial commitment to CBTTC, Advisory Council members saw the need to do more. Pooling their resources to create this grant fund incentivizes researchers to submit projects to the CBTTC. Since the inception of the fund in April of 2018, four projects have been funded.

Looking ahead to FY2019, the Advisory Council has enhanced its working structure by developing committees for fundraising and communication and looks forward to doing more together.

Al Gustafson
Executive Board Liaison for the CBTTC Advisory Council
Board Chair of the Swifty Foundation

2017-18 Advisory Council Members


A Look Ahead: Objectives for the Coming Year

The next fiscal year for the consortium will be defined by focus on sustainable growth and resource development. Our overall objective remains that by providing open access to biospecimens and the resulting datasets, CBTTC will fuel new discoveries and accelerate discovery of more effective treatments. Our commitment to that vision cultivated the objectives for the next fiscal year.

To Improve Operations Center Processes

  • Develop new tools to optimize operations
    • Operations Center Dashboard
    • Quality Control Tool for Clinical Data
  • Continue to improve practices to facilitate and accelerate scientific project requests and biospecimen/data distribution
  • Continue to facilitate regularly scheduled Clinical Data Working Group meetings to improve existing data and consider additional data elements
  • Develop a Clinical Genomic Diagnostic Working Group

To Increase CBTTC Scientific Productivity

  • Expansion of the Pediatric Brain Tumor Atlas (with open-access data sharing)
  • Perform additional data generation effort including WGS/RNAseq
  • Expand and integrate proteogenomic data generation efforts
  • Support single cell sequencing pilot data generation efforts
  • Integrate additional public datasets
  • Partner with and support additional consortia-based collaborations as part of grant-based team-science programs

Increase CBTTC capacity to generate patient derived cell lines and pre-clinical models

  • Pilot efforts for enhanced integration of AYA subjects and datasets
  • Integrate image-based analyses and molecular analyses in CBTTC platforms
  • Support enhanced clinical/phenotypic data harmonization and queriability
  • Initiate clinical sequencing data integration in the CBTTC
  • Perform and support cross-disease analyses
  • Enhance initiatives to characterize non-coding alterations across pediatric brain tumors
  • Support germ-line and predisposition analyses of pediatric brain tumors
  • Perform familial data generation and analyses pilots
  • Increase visibility at scientific meetings
  • Submit peer reviewed original scientific publications

To Develop a Sustainable Consortium and Support Growth

  • Apply for major infrastructure grants
  • Add an additional full member site by Q2 of FY18
  • Identify and on-board a new site by Q4 of FY18
  • Define metrics for site participation in the CBTTC
  • Engage with the Advisory Council to explore novel funding strategies

CBTTC Leadership

Executive Board Members

Ann & Robert H. Lurie Children’s Hospital of Chicago

Oren Becher, MD

Stewart Goldman, MD

Amanda Saratsis, MD

Children’s Hospital of Philadelphia

Michael Fisher, MD

Jena Lilly, MS

Jane Minturn, MD, PhD

Adam Resnick, PhD

Jay Storm, MD

Angela Waanders, MD, MPH – Executive Chair

UPMC Children’s Hospital of Pittsburgh

Ron Hamilton, MD

Ian Pollack, MD

Children’s National Health System

Javad Nazarian, PhD, MSc

Brian Rood, MD

Seattle Children’s Hospital

Russ Geyer, MD

Sarah Leary, MD

Lucile Packard Children’s Hospital Stanford

Gerald Grant, MD, FACS

Michelle Monje, MD, PhD

UCSF Benioff Children’s Hospital

Nalin Gupta, MD, PhD

Sabine Mueller, MD, PhD, MAS

Joanna Phillips, MD, PhD

Weill Cornell Medicine Pediatric Brain & Spine Center

Jeff Greenfield, MD, PhD

Children’s Brain Tumor Foundation

Anita Nirenberg – Community Representative

Swifty Foundation

Al Gustafson – Advisory Council Liaison

Scientific Committee Members

UPMC Children’s Hospital of Pittsburgh

Sameer Agnihotri, PhD

Ronald Hamilton, MD

Kimberly Diamond, BS

Gary Kohanbash, PhD

Ian Pollack, MD

Baoli Hu, PhD

Children’s Hospital of Philadelphia

Mateusz Koptyra, PhD

Adam Resnick, PhD – Co-Chair

Mariarita Santi-Vicini, MD, PhD

Phillip (Jay) Storm, MD

Angela Waanders, MD, MPH

Kristina Cole, MD, PhD

Seattle Children’s Hospital

Sarah Leary, MD

Courtney Crane, PhD

Jim Olson, MD, PhD

Andy Strand, PhD

Bonnie Cole, MD

Ann & Robert H. Lurie Children’s Hospital of Chicago

Nitin Wadhwani, MD

Amanda Saratsis, MD

Oren Becher, MD

UCSF Benioff Children’s Hospital

Joanna Phillips, MD, PhD

Sabine Mueller, MD, PhD, MAS

Nalin Gupta, MD, PhD

Lucile Packard Children’s Hospital Stanford

Michelle Monje, MD, PhD

Gerald Grant, MD, FACS

Children’s National Health System

Brian Rood, MD

Javad Nazarian, PhD, MSc – Co-Chair

Eugene Hwang, MD

Suresh Magge, MD

Robert Keating, MD

Weill Cornell Medicine Pediatric Brain & Spine Center

Jeff Greenfield, MD, PhD

David Pisapia, MD

Christopher Mason, PhD

Olivier Elemento, PhD

Praveen Raju, MD, PhD

UCSC Treehouse Childhood Cancer Initiative

Olena Morozova, PhD

Holly Beale, PhD

Sofie Salama, PhD

Meyer Children’s Hospital

Mirko Scagnet, MD

Anna Maria Buccoliero, MD, PhD

Chiara Caporalini, MD

Hackensack Meridian Health Network

Derek Hanson, MD

Dayton Children’s Hospital

Robert Lober, MD, PhD

Ayman El-Sheikh, MD

Beijing Tiantan Hospital Neurosurgery/Genebank

Shida Zhu, MS

The Hudson Institute of Medical Research

Jason Cain, PhD

Dragon Master Foundation

Amanda Haddock – Advisory Council Liaison


About the CBTTC

The Children’s Brain Tumor Tissue Consortium (CBTTC) is a collaborative, multi-institutional research program dedicated to the study and treatment of childhood brain tumors. The CBTTC supports the research of new prognostic biomarkers and therapies for the effective treatment of children with brain tumors. As part of this research effort, the CBTTC has developed a network of informatics and data applications which allow researchers from across the world to work together to discover cures. “Innovation through collaboration” is made possible by the CBTTC’s state-of-the-art biorepository as well as expertise of leaders in the field of biomedicine.

The CBTTC consists of 16 national and international member institutions including: 1) Children’s Hospital of Philadelphia, 2) Seattle Children’s, 3) UPMC Children’s Hospital of Pittsburgh, 4) Ann & Robert H. Lurie Children’s Hospital of Chicago, 5) Benioff Children’s Hospital (UCSF), 6) Lucile Packard Children’s Hospital Stanford, 7) Meyer Children’s Hospital (Florence Italy), 8) Weill Cornell Medicine Pediatric Brain and Spine Center, 9) Children’s National Health System, 10) Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center, 11) Children’s Hospital of Orange County (CHOC Children’s), 12) UCSCTreehouse Childhood Cancer Initiative 13) Beijing Tiantan Hospital Neurosurgery Center (Beijing, China), 14) Genebank (Beijing Genomics Institute – Shenzhen, China), 15) Dayton Children’s Hospital, and 16) The Hudson Institute of Medical Research (Melbourne, Australia).

The operations center of the CBTTC is located at Children’s Hospital of Philadelphia and integrates genomic and molecular research, biorepository management, and support for the informatics platforms of the CBTTC. This infrastructure serves an important role in the CBTTC’s ability to provide free and open access to brain tumor data to researchers throughout the world.

To learn more about collaborating with the Children’s Brain Tumor Tissue Consortium, visit cbttc.org or email research@cbttc.org

Connect with the CBTTC on social media!

 

 


Acknowledgement

The entire membership and staff of the Children’s Brain Tumor Tissue Consortium would like thank Dr. Rishi Lulla for his dedication and service as Chair of the CBTTC Executive Committee (2016-2018).

Through his exceptional leadership, the CBTTC underwent unparalleled growth and expansion. Dr. Lulla’s leadership allowed CBTTC to grow while being mindful of sustainability and accountability. As Executive Chair, Dr. Lulla led the CBTTC Executive Committee in defining annual objectives all aimed at the ultimate goal to provide more effective treatments for children with CNS tumors.

We express our sincere gratitude for his guidance and expertise in leading the consortium successfully for those two years. We wish him all the best in his new role as the Division Chief of Pediatric Hematology/Oncology at Hasbro Children’s Hospital at Brown University.


Download the 2017-18 CBTTC Annual Report